This approach was cautious, and with an improved understanding of the increased risk of ketoacidosis specifically in people taking SGLT2 inhibitors (and following a ketogenic diet, a predisposing factor for developing this),23 future recommendations would be to only exclude people with type II diabetes prescribed this medication class. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.